Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 4/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | P4HB | P07237 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 10/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | CCR3 | P51677 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3043524 | 0.89 | BRD4 (0.35) | P4HBBRD4CREBBPNR1H2NR1H3 | |
| SCHEMBL3047029 | 0.88 | NR1H2 (0.37) | BRD4CREBBPPOLBNR1H2NR1H3 | |
| SCHEMBL3047413 | 0.88 | NR1H2 (0.36) | BRD4CREBBPPOLBNR1H2NR1H3 | |
| SCHEMBL3047734 | 0.87 | VEGFA (0.40) | NR1H2 | |
| SCHEMBL5048301 | 0.87 | BRD4 (0.37) | BRD4CREBBPNR1H2NR1H3CHRM4 | |
| SCHEMBL3050056 | 0.86 | ATR (0.41) | BRD4CREBBPPOLBNR1H2NR1H3 | |
| SCHEMBL3046498 | 0.86 | NR1H2 (0.35) | BRD4CREBBPNR1H2NR1H3 | |
| SCHEMBL3044252 | 0.86 | BRD4 (0.36) | BRD4CREBBPNR1H2NR1H3 | |
| SCHEMBL3034090 | 0.86 | LTA4H (0.36) | BRD4CREBBPNR1H2NR1H3 | |
| SCHEMBL3054418 | 0.86 | NR1H2 (0.37) | BRD4CREBBPNR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7745641-B2 | Nitrogen-containing heterocyclic compound | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-06-29 | — | — | US | disclosed |
| US-20090054407-A1 | Nitrogen-containing heterocyclic compound | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-02-26 | — | — | US | disclosed |
| EP-1880993-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2008-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054407-A1 | Nitrogen-containing heterocyclic compound | NR4A1, NR5A2, PRMT8 | OPRL1 513/4885OPRM1 301/4885P4HB 2400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.